Lung Cancer


Patients With NSCLC Are Not Undergoing Biomarker Testing for Precision Medicines-Patient Education is Key (March 14, 2017)

Despite guidelines recommending testing, patients with stage IV non-small cell lung cancer (NSCLC) who are treated in the community setting are undergoing EGFR/ALK biomarker testing.1 Doctors are currently... Continue Reading

Advances in Immunotherapy Starting to Define Cancer Treatment (March 9, 2017)

T cell lymphocyte with receptors to kill cancer cell in cancer immunotherapy A handful of drugs recently developed and approved by the United States Food and Drug Administration are expanding the emerging... Continue Reading

Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC (March 7, 2017)

The US Food and Drug Administration (FDA) granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC)... Continue Reading

Recent Advances in The Management of Lung Cancer (March 3, 2017)

The last 12 months continue to show advances in the treatment of non-small cell lung cancer (NSCLC), once again most notably in the sector of precision treatment. Importantly advances in the treatment... Continue Reading

Lung Cancer Treatment Gets Personal (January 29, 2017)

Recent advances highlight the power of precision medicine. By Charles H. Weaver, MD Recently, there have been more exciting new approaches to managing non–small cell lung cancer (NSCLC) than at any time... Continue Reading

Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from... Continue Reading

Keytruda® Data Demonstrating Activity in Mesothelioma Presented at 17th World Conference on Lung Cancer (January 3, 2017)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) were featured in an oral presentation at the 17th World Conference on Lung Cancer hosted... Continue Reading

Keytruda® Active in Small Cell Lung Cancer (December 28, 2016)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference... Continue Reading

Tagrisso®: New Standard of Care for Certain Lung Cancer (December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell... Continue Reading

Pass It On: It’s National Lung Cancer Awareness Month (November 2, 2016)

There are several types of lung cancer: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma and lung carcinoid tumors, with NSCLC and SCLC accounting for about 95% of diagnoses... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of... Continue Reading

FDA Approves Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer (October 20, 2016)

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer... Continue Reading

Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues (October 14, 2016)

Voices of Value Speak Up: Non-Small Cell Lung Cancer is the first part of a national six-event program presented by Patients Rising and Aimed Alliance. Where is the patient in the national conversation... Continue Reading

Staging (October 11, 2016)

Staging: Determining the stage or extent of spread of the cancer is essential in order to understand treatment options or interpret published cancer treatment information. Determining the stage of lung... Continue Reading

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (September 14, 2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (September 13, 2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS